WallStSmart

Insmed Inc (INSM)vsLineage Cell Therapeutics Inc (LCTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 4066% more annual revenue ($606.42M vs $14.56M). LCTX leads profitability with a 0.0% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

LCTX

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -3.83

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

LCTX2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
130.4%10/10

Revenue surging 130.4% year-over-year

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

LCTX4 concerns · Avg: 3.5/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$366.16M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : LCTX

The strongest argument for LCTX centers on Revenue Growth, Debt/Equity. Revenue growth of 130.4% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : LCTX

The primary concerns for LCTX are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while LCTX is a hypergrowth play — different risk/reward profiles.

LCTX carries more volatility with a beta of 1.76 — expect wider price swings.

LCTX is growing revenue faster at 130.4% — sustainability is the question.

LCTX generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Lineage Cell Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.

Visit Website →

Want to dig deeper into these stocks?